Catalyst Event
Gilead Sciences Inc (GILD) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/29/2026, 12:00:00 AM
The U.S. FDA accepted Gilead's New Drug Application (NDA) for its once-daily single-tablet HIV treatment combination, bictegravir/lenacapavir, and granted it priority review with a PDUFA action date set for August 27, 2026, which is scheduled. High importance is estimated as this is a key pipeline milestone.
Korean Translation
미국 FDA가 길리어드의 1일 1회 단일정 HIV 치료제 복합제인 빅테그라비르/레나카파비르에 대한 신약 허가 신청(NDA)을 접수하고, 우선 심사 대상으로 지정함. PDUFA 결정일은 2026년 8월 27일로 예정됨. 주요 파이프라인 마일스톤으로서 중요도를 'High'로 예상함.
Related Recent Events
Bristol-Myers Squibb Co (BMY) · Other
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.
8/17/2026, 12:00:00 AM
Blackstone Inc (BX) · Earnings Release
Blackstone is scheduled to release its Q2 2026 earnings results, with analysts forecasting earnings of approximately $1.34-$1.36 per share, scheduled.
7/23/2026, 12:00:00 AM
Union Pacific Corp (UNP) · Earnings Release
Q2 2026 earnings release is scheduled. Low impact estimated as the date announcement is a routine event; scheduled.
7/23/2026, 12:00:00 AM
Goldman Sachs Group Inc (The) (GS) · Earnings Release
Goldman Sachs' Q2 2026 earnings release is scheduled.
7/14/2026, 12:00:00 AM
NIKE Inc (NKE) · Earnings Release
Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.
6/25/2026, 12:00:00 AM
Vistra Corp (VST) · Other
Quarterly dividend of $0.2290 per share with an ex-dividend date of June 22, 2026; low importance estimated as dividends usually cause minor price adjustments, scheduled.
6/22/2026, 12:00:00 AM